Agios Pharmaceuticals | AGIO - Ebitda


Agios Pharmaceuticals reported $-115.49M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Astellas Pharma JPY 183.68B 31.98B Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bayer EUR 1.97B 457M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.88B 290M Sep/2025
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025